January 06, 2023
A new comparative study found the use of prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) led to treatment changes in nearly 20 percent of patients with high-risk prostate cancer.
December 22, 2022
Catch up on the top AI-related news and research of the past month.
December 17, 2022
Check out the top radiology content of the past week.
December 12, 2022
In a study of nearly 18,000 men who had prostate cancer screening, researchers found the use of pre-biopsy magnetic resonance imaging (MRI) for those with elevated prostate-specific antigen (PSA) levels and reserving MRI-targeted biopsy for those with PI-RADS scores of 3 to 5 reduced the risk of detecting clinically insignificant cancers by half.
December 10, 2022
Catch up on the top radiology content of the past week.
December 07, 2022
The Food and Drug Administration has granted 510(k) clearance to iQuest (Avenda Health), an artificial intelligence (AI) platform that combines findings from magnetic resonance imaging (MRI), pathology reports and biopsy results to facilitate three-dimensional mapping of prostate cancer.
December 06, 2022
For patients recently diagnosed with prostate cancer, the emerging positron emission tomography (PET) agent 18F-rhPSMA-7.3 reportedly has a 96 percent specificity rate for detecting pelvic lymph node metastases, according to Phase 3 study results recently presented at the 22nd Annual Scientific Meeting of the Society of Urologic Oncology (SUO).
December 03, 2022
Catch up on the top radiology content of the past week.
December 01, 2022
In what may be the first study to assess the effectiveness of biparametric magnetic resonance imaging (MRI) for prostate cancer screening in a large cohort, researchers found that MRI screening had a significantly lower false positive rate and significantly higher positive predictive values (PPVs) than prostate-specific antigen (PSA)-based screening.
November 07, 2022
New research shows that 18F-NaF PET/CT had higher sensitivity, accuracy, and negative predictive value than 99mTc-MDP SPECT for bone metastases in patients deemed to be at high risk for prostate cancer or breast cancer.